antibiotics, and diagnostics.

Current research and commercial entities have prioritized employing nanocarrier technology to both create new applications (e.g., mRNA and plasmid vaccines) and enhance the delivery/efficacy of current chemical/active ingredients (e.g., traditional antibiotics) while reducing negative effects and environmental impact. Our BAPC and CAPC platforms offer significant advantages in developing new commercially viable products and improving established product lines. The current nanocarriers available today have many limitations in these applications, and there are no competitors using self-assembling, customizable peptide nanocarriers that deliver our unique benefits.